Antithymocyte Globulin
- Atc Codes:L04AA03
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Latvia: Atgam; Slovenia: Atgam.
North America
Canada: Atgam; USA: Atgam.
Latin America
Mexico: Atgam.
Asia
Japan: Lymphoglobuline.
Drug combinations
Chemistry
Pharmacologic Category
Immunosuppressive Agents; Immune Globulin. (ATC-Code: L04AA03).
Mechanism of action
May involve elimination of antigen-reactive T lymphocytes (killer cells) in peripheral blood or alteration of T-cell function.
Therapeutic use
Prevention and treatment of acute renal allograft rejection. Treatment of moderate to severe aplastic anemia in patients not considered suitable candidates for bone marrow transplantation.
Pregnancy and lactiation implications
Use during pregnancy is not recommended. Use with caution during lactation.
Unlabeled use
Prevention and treatment of other solid organ allograft rejection. Prevention of graft vs host disease following bone marrow transplantation.
Contraindications
Hypersensitivity to lymphocytic immune globulin, any component of the formulation, or other equine γ-globulins.
Warnings and precautions
Hypersensitivity and anaphylactic reactions can occur. Rash, dyspnea, hypotension, or anaphylaxis precludes further administration of the drug. Discontinue if severe and unremitting leukopenia or unremitting thrombocytopenia occur. Must be administered via central line due to chemical phlebitis. Intradermal skin testing is recommended prior to first-dose administration.